These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32525060)

  • 1. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of the 5-HT
    de Jong IEM; Mørk A
    Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update.
    Khoury R; Grysman N; Gold J; Patel K; Grossberg GT
    Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual 5-HT
    Grychowska K; Chaumont-Dubel S; Kurczab R; Koczurkiewicz P; Deville C; Krawczyk M; Pietruś W; Satała G; Buda S; Piska K; Drop M; Bantreil X; Lamaty F; Pękala E; Bojarski AJ; Popik P; Marin P; Zajdel P
    ACS Chem Neurosci; 2019 Jul; 10(7):3183-3196. PubMed ID: 30896921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease.
    Werner FM; Covenas R
    Curr Pharm Des; 2016; 22(14):2064-71. PubMed ID: 26818863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K; Haupt A; Bespalov A
    Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT6 receptors: a novel target for cognitive enhancement.
    Mitchell ES; Neumaier JF
    Pharmacol Ther; 2005 Dec; 108(3):320-33. PubMed ID: 16005519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT
    Saavedra OM; Karila D; Brossard D; Rojas A; Dupuis D; Gohier A; Mannoury la Cour C; Millan MJ; Ortuno JC; Hanessian S
    Bioorg Med Chem; 2017 Jan; 25(1):38-52. PubMed ID: 28029458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.
    Upton N; Chuang TT; Hunter AJ; Virley DJ
    Neurotherapeutics; 2008 Jul; 5(3):458-69. PubMed ID: 18625457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.
    Nirogi R; Jayarajan P; Shinde A; Mohammed AR; Grandhi VR; Benade V; Goyal VK; Abraham R; Jasti V; Cummings J
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idalopirdine as a treatment for Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2015; 24(7):981-7. PubMed ID: 26022777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders.
    Millan MJ; Rivet JM; Gobert A
    J Psychopharmacol; 2016 Nov; 30(11):1099-1128. PubMed ID: 27756833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of dopamine D₃ receptor neurotransmission in cognition.
    Nakajima S; Gerretsen P; Takeuchi H; Caravaggio F; Chow T; Le Foll B; Mulsant B; Pollock B; Graff-Guerrero A
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):799-813. PubMed ID: 23791072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating 5-HT
    Lalut J; Karila D; Dallemagne P; Rochais C
    Future Med Chem; 2017 May; 9(8):781-795. PubMed ID: 28504917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
    Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
    Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 5-HT
    Chaumont-Dubel S; Dupuy V; Bockaert J; Bécamel C; Marin P
    Neuropharmacology; 2020 Aug; 172():107839. PubMed ID: 31682856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease.
    Hirano K; Piers TM; Searle KL; Miller ND; Rutter AR; Chapman PF
    Life Sci; 2009 Apr; 84(15-16):558-62. PubMed ID: 19302808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical update on the potential for serotonin 5-HT
    Kucwaj-Brysz K; Baltrukevich H; Czarnota K; Handzlik J
    Bioorg Med Chem Lett; 2021 Oct; 49():128275. PubMed ID: 34311086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.